



TABLE OF CONTENTS

1. Scheme S1. Synthesis of FAP targeting ligand (FL).
2. Figure S1. Chemical structure and LC/MS trace of Compound 3.
3. Figure S2. Chemical structure and LC/MS trace of Compound 4.
4. Figure S3. Chemical structure and LC/MS trace of Compound 5.
5. Figure S4. Chemical structure and LC/MS trace of Compound 7.
6. Figure S5. Chemical structure and LC/MS trace of Compound 8 (FL).
7. Scheme S2. Synthesis of FL-L1-S0456 and FL-L1-FITC.
8. Figure S6. Chemical structure and LC/MS trace of FL-L1.
9. Figure S7. Chemical structure and LC/MS trace of FL-L1-FITC.
10. Figure S8. Chemical structure and LC/MS trace of FL-L1-S0456.
11. Scheme S3. Synthesis of FL-L3.
12. Figure S9. Chemical structure, LC/MS trace, and ^1H NMR of Compound 10.
13. Figure S10. Structure and LC/MS of FAP conjugate (FL-L3).
14. Scheme S4. Radioactive labeling of FL-L3 with $^{99\text{m}}\text{Tc}$ and radio HPLC.
15. Scheme S5. Synthesis of FL-L1-TubBH.
16. Figure S11. Structure and LC/MS of FAP tubulysin B hydrazide conjugate (FL-L1-TubBH).
17. Figure S12. Confocal Imaging and in vitro binding affinity of FL-L1-FITC and FL-L1-S0456.
18. Figure S13. In vitro binding affinity and cytotoxicity plots.
19. Figure S14. Representative flow cytometry histograms to determine FAP expression on HEK293-hFAP cells and FAP mediated specific binding of FL-L1-FITC.




1

2 **Scheme S1.** Synthesis of FAP targeting ligand (FL). Reagents and conditions: a) HATU, Anhy.
 3 DIPEA, Anhy. DMF, rt; b) TFAA, Anhy. DCM, Anhy. Pyridine, rt; c) TFA, rt; d) HATU, Anhy. DIPEA,
 4 Anhy. DMF, rt; e) TFA, rt.




7 **Figure S1.** Chemical structure and LC/MS trace of Compound 3.



1

2

Figure S2. Chemical structure and LC/MS trace of Compound 4.



3

4

Figure S3. Chemical structure and LC/MS trace of Compound 5.


5

6

7


8

9



1

2 **Figure S4.** Chemical structure and LC/MS trace of Compound 7.



3



4 **Figure S5.** Chemical structure and LC/MS trace of Compound 8 (FL).

5



6

7



8




7 **Figure S6.** Chemical structure and LC/MS trace of FL-L1.



1
2
3
4 **Figure S7.** Chemical structure and LC/MS trace of FL-L1-FITC.
5
6



7
8 **Figure S8.** Chemical structure and LC/MS trace of FL-L1-S0456.
9



Scheme S3. Synthesis of FL-L3. Reagents and conditions: (a) (i) 20% piperidine/DMF, rt, (ii) Fmoc-Asp(OtBu), PyBop, DMF, DIPEA, (b) (i) 20% piperidine/DMF, rt, 10 min (ii) Fmoc-diaminopropionic (DAP) acid, PyBop, DMF, DIPEA, (c) (i) 20% piperidine/DMF, rt, (ii) Fmoc-8-amino-octanoic acid, PyBop, DMF, DIPEA, (d) (i) 20% piperidine/DMF, rt, 10 min (ii) Compound 10, PyBop, DMF, DIPEA, (iii) TFA/H₂O/TIPS/EDT (92.5:2.5:2.5:2.5), 1 h. The crude product was purified by using HPLC and characterized by using LC/MS.





Figure S9. Chemical structure, LC/MS trace, and ^1H NMR of Compound 10.

^1H NMR (500 MHz, Deuterium Oxide) δ 8.58 – 8.47 (d, J = 4.8 Hz, 1H), 7.67 – 7.40 (m, 2H), 5.10 – 5.02 (dd, J = 9.1, 4.3 Hz, 1H), 4.64 – 4.54 (q, J = 7.2 Hz, 1H), 4.45 (s, 2H), 4.22 - 4.13 (m, 2H), 3.05 – 2.70 (m, 2H), 2.55 (s, 4H), 1.43 – 1.33 (d, J = 7.1 Hz, 3H).






Figure S10. Structure and LC/MS of FAP conjugate (FL-L3).


1
2
3



4

Scheme S4. Radioactive labeling of FL-L3 with ^{99m}Tc and radio HPLC. Reagents and conditions: (a) ^{99m}Tc sodium pertechnetate (15 mCi, 1 ml), 100 °C, 18 min. Chelation efficiency was confirmed by radio HPLC.

8




9

Scheme S5. Synthesis of FL-L1-TuBH. Reagents and conditions: a. (i) FL-L1, $\text{H}_2\text{O}/\text{NaHCO}_3$ (pH=7.0-7.2), Argon, r.t. (ii) activated TubBH, anhydrous THF, argon, r.t.


12

1
2
3



4
5
6


Figure S11. Structure and LC/MS of FAP tubulysin B hydrazide conjugate (FL-L1-TubBH).




7
8
9
10
11
12
13
14

Figure S12. Confocal Imaging and in vitro binding affinity of FL-L1-FITC and FL-L1-S0456. A. The cancer cells were incubated with FL-L1-FITC (100 nM) at 37°C. After incubating for 1 h the cells were washed with medium to remove unbound dye conjugate and observed under confocal microscopy. B. HEK293-FAP cancer cells were incubated with FL-L1-S0456 in the presence or absence of 100-fold excess of FL at 37°C. After incubating for 1 h the cells were washed with medium to remove unbound dye conjugate. Cells were dissolved with 1% SDS and the cell bound fluorescence was measured using a fluorimeter. The K_d represents the specific binding of FL-L1-S0456 for FAP. C. MDA-MB231

1 tumor-bearing mice were injected with FL-L1-S0456 (green), the tumors were excised, sectioned and
 2 stained for cancer epithelial cell marker (EpCAM, red) and nuclei (DAPI, blue).



3
 4 **Figure S13.** In vitro binding affinity and cytotoxicity plots. A. In vitro binding of FL-L1-^{99m}Tc. hFAP
 5 transfected HEK293 cells were incubated with various concentrations of FL-L3-^{99m}Tc either in the
 6 presence or absence of 100-fold excess of FL. The cell bound radioactivity was determined by
 7 gamma counting. K_d value was determined by using GraphPad Prism 7. B. In vitro cytotoxicity of FL-
 8 L1-TubBH. HLF1 cells transfected with hFAP were incubated with various concentrations of FL-L1-
 9 TubBH and the cell viability was determined by using “*Cell Titer-Glo® Luminescent Cell Viability*
 10 *Assay kit*”. The cell luminescence was determined and plotted in GraphPad Prism 7 to determine the
 11 IC_{50} .



13
 14 **Figure S14.** Representative flow cytometry histograms to determine FAP expression on HEK293-
 15 hFAP cells and FAP mediated specific binding of FL-L1-FITC. Histograms represent A) unstained
 16 control cells B) viable cells determined by 7AAD staining C) binding of cells to FL-L1-FITC dye
 17 conjugate (FITC-FAP+7AAD) D) binding of cells to FL-L1-FITC in the presence of 100-fold excess of
 18 FL to determine specificity (FITC-FAP+competition+7AAD).